Topic: Combination Therapy for Advanced HCC

Multidisciplinary treatment of unresectable advanced hepatocellular carcinoma (HCC) has garnered significant interest in recent years due to the development of systemic chemotherapies over the past 5-7 years. In the past, hepatic arterial chemoembolization and continuous hepatic arterial therapy were used as local treatments for advanced HCC. However, in recent times, the landscape of drug therapies has expanded with the advent of molecular targeted therapies, immune checkpoint inhibitors, and other drug therapies. Furthermore, the combination of drug therapy with hepatic resection has improved treatment outcomes for advanced unresectable HCC. Conversion surgery is increasingly being considered for patients with downsizing and downstaging after drug therapy. In this Special Issue, we would like to provide an overview of the multidisciplinary treatment for unresectable HCC, including pharmacotherapy, pathology, local treatment, and conversion surgery.

Potential topics include, but are not limited to, the following:
1. Treatment strategies for unresectable advanced HCC;
2. Drug therapy for unresectable advanced HCC;
3. Pathology after drug treatment of HCC;
4. Conversion surgery for unresectable advanced HCC;
5. Hepatic coagulation for advanced unresectable HCC;
6. Treatment strategies for intermediate-stage HCC of BCLC;
7. Multidisciplinary treatment for advanced-stage HCC with vascular invasion;
8. The significance of surgical resection in unresectable advanced HCC;
9. Postoperative adjuvant chemotherapy for advanced HCC;
10. Adverse effects of immune checkpoint inhibitors;
11. Appropriate use of immune checkpoints and molecular-targeted therapies for advanced HCC;
12. Frontline of TACE or chemoradiotherapy for multiple HCCS;
13. Radiotherapy for advanced HCC;
14. The outcome of liver surgery, local treatment, and drug therapy for advanced HCC.

15 Jul 2024